Financhill
Buy
60

LMAT Quote, Financials, Valuation and Earnings

Last price:
$94.24
Seasonality move :
2.06%
Day range:
$90.76 - $92.63
52-week range:
$52.88 - $109.58
Dividend yield:
0.69%
P/E ratio:
50.62x
P/S ratio:
9.85x
P/B ratio:
6.29x
Volume:
55.6K
Avg. volume:
178.3K
1-year change:
62.71%
Market cap:
$2.1B
Revenue:
$193.5M
EPS (TTM):
$1.83

Analysts' Opinion

  • Consensus Rating
    LeMaitre Vascular has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $98.78, LeMaitre Vascular has an estimated upside of 6.64% from its current price of $92.63.
  • Price Target Downside
    According to analysts, the lowest downside price target is $85.00 representing 100% downside risk from its current price of $92.63.

Fair Value

  • According to the consensus of 7 analysts, LeMaitre Vascular has 6.64% upside to fair value with a price target of $98.78 per share.

LMAT vs. S&P 500

  • Over the past 5 trading days, LeMaitre Vascular has underperformed the S&P 500 by -1.05% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • LeMaitre Vascular does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • LeMaitre Vascular has grown year-over-year revenues for 17 quarters straight. In the most recent quarter LeMaitre Vascular reported revenues of $54.8M.

Earnings Growth

  • LeMaitre Vascular has grown year-over-year earnings for 6 quarters straight. In the most recent quarter LeMaitre Vascular reported earnings per share of $0.49.
Enterprise value:
2B
EV / Invested capital:
5.92x
Price / LTM sales:
9.85x
EV / EBIT:
37.75x
EV / Revenue:
9.20x
PEG ratio (5yr expected):
0.99x
EV / Free cash flow:
58.49x
Price / Operating cash flow:
62.64x
Enterprise value / EBITDA:
31.84x
Gross Profit (TTM):
$145.6M
Return On Assets:
11.64%
Net Income Margin (TTM):
19.4%
Return On Equity:
13.37%
Return On Invested Capital:
13.37%
Operating Margin:
23.98%
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Income Statement
Revenue $160.2M $185.6M $213M $47.4M $54.8M
Gross Profit $104.8M $119.8M $145.6M $30.8M $37.2M
Operating Income $31.3M $34M $49.6M $9.2M $13.1M
EBITDA $41.4M $40.9M $61.5M $11.6M $15.6M
Diluted EPS $0.96 $1.21 $1.83 $0.33 $0.49
Period Ending 2020-09-30 2021-09-30 2022-09-30 2023-09-30 2024-09-30
Balance Sheet
Current Assets $102.3M $134M $153.1M $182.2M $227.1M
Total Assets $261.6M $289.5M $302M $334M $377M
Current Liabilities $44.4M $22.1M $23.4M $29M $29.3M
Total Liabilities $100.6M $40.4M $40.8M $45.4M $46M
Total Equity $161M $249M $261.2M $288.6M $331.1M
Total Debt $59.5M -- -- -- --
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Cash Flow Statement
Cash Flow Operations $26.4M $30.1M $39.7M $11.8M $14.2M
Cash From Investing -$17.2M -$22.9M -$28.5M -$9.9M -$12.9M
Cash From Financing -$8.3M -$6.6M -$8.7M -$3.1M -$3.1M
Free Cash Flow $23.8M $22.8M $33.5M $10.8M $12.6M
LMAT
Sector
Market Cap
$2.1B
$46.1M
Price % of 52-Week High
84.53%
46.02%
Dividend Yield
0.69%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
62.71%
-30.52%
Beta (5-Year)
0.933
0.772
Dividend yield:
0.69%
Annualized payout:
$0.56
Payout ratio:
33.63%
Growth streak:
0 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Sell
Level $92.80
200-day SMA
Buy
Level $83.99
Bollinger Bands (100)
Sell
Level 85.46 - 99.94
Chaikin Money Flow
Buy
Level 22.4M
20-day SMA
Sell
Level $98.88
Relative Strength Index (RSI14)
Sell
Level 38.68
ADX Line
Buy
Level 7.26
Williams %R
Neutral
Level -74.3389
50-day SMA
Sell
Level $97.52
MACD (12, 26)
Sell
Level -2.39
25-day Aroon Oscillator
Sell
Level -68
On Balance Volume
Neutral
Level 19.2M

Financial Scores

Buy
Altman Z-Score (Annual)
Level (17.5262)
Buy
CA Score (Annual)
Level (1.9662)
--
Beneish M-Score (Annual)
Level (--)
Buy
Momentum Score
Level (10)
Buy
Ohlson Score
Level (-3.9437)
Buy
Piotroski F Score (Annual)
Level (8)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (10)

Revenue Forecast

Earnings per Share Forecast

Company Profile

LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.

Stock Forecast FAQ

In the current month, LMAT has received 4 Buy ratings 3 Hold ratings, and 0 Sell ratings. The LMAT average analyst price target in the past 3 months is $98.78.

  • Where Will LeMaitre Vascular Stock Be In 1 Year?

    According to analysts, the consensus estimate is that LeMaitre Vascular share price will rise to $98.78 per share over the next 12 months.

  • What Do Analysts Say About LeMaitre Vascular?

    Analysts are divided on their view about LeMaitre Vascular share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that LeMaitre Vascular is a Sell and believe this share price will drop from its current level to $85.00.

  • What Is LeMaitre Vascular's Price Target?

    The price target for LeMaitre Vascular over the next 1-year time period is forecast to be $98.78 according to 7 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.

  • Is LMAT A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for LeMaitre Vascular is a Buy. 4 of 7 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of LMAT?

    You can purchase shares of LeMaitre Vascular via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase LeMaitre Vascular shares.

  • What Is The LeMaitre Vascular Share Price Today?

    LeMaitre Vascular was last trading at $94.24 per share. This represents the most recent stock quote for LeMaitre Vascular. Yesterday, LeMaitre Vascular closed at $92.63 per share.

  • How To Buy LeMaitre Vascular Stock Online?

    In order to purchase LeMaitre Vascular stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Is SoundHound AI Stock Up So Much?
Why Is SoundHound AI Stock Up So Much?

Like many companies improving AI technologies and exploring ways to…

Is The Santa Claus Rally The Gift That Keeps Giving?
Is The Santa Claus Rally The Gift That Keeps Giving?

Remember the horror of 2008 when the Great Recession hit…

Is Alphabet an Undervalued Growth Stock to Buy?
Is Alphabet an Undervalued Growth Stock to Buy?

Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…

Stock Ideas

Buy
65
Is AAPL Stock a Buy?

Market Cap: $3.9T
P/E Ratio: 42x

Buy
57
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 118x

Buy
58
Is MSFT Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 37x

Alerts

Buy
60
QMCO alert for Dec 26

Quantum [QMCO] is up 49.62% over the past day.

Buy
53
ARQQ alert for Dec 26

Arqit Quantum [ARQQ] is up 49.85% over the past day.

Buy
65
TSLL alert for Dec 26

Direxion Daily TSLA Bull 2X Shares [TSLL] is down 3.73% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock